Hepatic injury in a patient taking rosiglitazone

Journal of Clinical Gastroenterology

Volumn 39, Issue 7, 2005, Pages 638-640

  Menees, Stacy B ^a   Anderson, Michelle A ^a   Chensue, Stephen W ^a   Moseley, Richard H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Drug related liver injury; Thiazolidinediones

Indexed keywords

BILE PIGMENT; ROSIGLITAZONE;

ADULT; ARTICLE; BILE; CASE REPORT; CHOLESTATIC HEPATITIS; HUMAN; HUMAN TISSUE; INTRAHEPATIC BILE DUCT; KUPFFER CELL; LIVER BIOPSY; LIVER INJURY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

BIOPSY; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; FATAL OUTCOME; HEPATITIS, CHRONIC, DRUG-INDUCED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 23044450857     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000170768.59696.16     Document Type: Article

References (19)

1. Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation. Ann Intern Med. 1998;129:38-41.
2. Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129:36-38.
3. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474-485.
4. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology. 2002;122:1822-1828.
5. Chan KA, Truman A, Gurwitz JH, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med. 2003;163:728-734.
6. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-121.
7. Gouda HE, Khan A, Schwartz J, Cohen RI. Liver failure in a patient treated with long-term rosiglitazone therapy. Am J Med. 2001;111:584-585.
8. Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med. 2000;132:121-124.
9. Dhawan M, Agrawal R, Ravi J, et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol. 2002;34:582-584.
10. Hachey DM, O'Neil MP, Force RW. Isolated elevation of alkaline phosphatase level associated with rosiglitazone. Ann Intern Med. 2000;133:752.
11. Bonkovsky HL, Azar R, Bird S, et al. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci. 2002;47:1632-1637.
12. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis. 2004;38(suppl):44-48.
13. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care. 2002;25:815-821.
14. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med. 2001;135:306.
15. Nagasaka S, Abe T, Kawakami I, et al. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success. Diabetes Med. 2002;19:344-348.
16. Chase MP, Yarze JC. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol. 2002;97:502-503.
17. May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002;136:449-452.
18. Pinto AG, Cummings OW, Chalasani N. Severe but reversible cholestatic liver injury after pioglitazone therapy. Ann Intern Med. 2002;137:857.
19. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460-468.